N/A N=15 Presence or Absence of Blood in the GI Lumen
Upper GI Bleeding
Primary: Number of Participants With True Positive Results — 3 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=162 Comparing Early Versus Elective Colonoscopy
Acute Lower Gastrointestinal Bleeding
Primary: Stigmata of Recent Hemorrhage (SRH) Identification Rate — 17; 17 Participants
N/A N=24 Capsule Endoscopy for HEmorrhage in the ER
Upper Gastrointestinal Bleeding
Primary: Number of Participants Discharged for Outpatient Management of Upper GI Bleeds — 3; 9 Participants
N/A N=35 Study of Early Endocapsule (EC) in Clinical Decision Unit Versus Standard of Care Work-up for GI Bleeding
Gastro Intestinal Bleeding · Hematemesis · Melena
Primary: Rate of Detection of Bleeding — 11; 11 Participants
N/A N=339 Risk Factors for Rebleeding in Patients With Obscure Gastrointestinal Bleeding
Gastrointestinal Bleeding
Primary: Rebleeding Rate — 97 participants
N/A N=235 Doppler Ultrasound Probe for Blood Flow Detection in Severe Upper Gastrointestinal Hemorrhage
UGI Bleeding · Ulcer or Variceal Hemorrhage · Stigmata of Recent Hemorrhage
Primary: 30 Day Rebleeding Rate — 20; 8; 17; 6 Participants
Phase 4 N=166 Argon Plasma Coagulation vs Hemoclipping for Bleeding Peptic Ulcers
Bleeding Peptic Ulcer
Primary: Number of Participants With Rebleeding — 3; 4 Participants
N/A N=87 Comparing Early Capsule Deployment to Current Standard of Care for Management of Gastrointestinal Bleeding
Melena · Gastrointestinal Hemorrhage
Primary: Time to Localization of Bleeding — 21; 16 hours — p=.002
N/A N=30 Detection of Upper Gastrointestinal (GI) Bleeding With a Novel Bleeding Sensor Capsule [DING]
Upper GI Bleeding
Primary: Number of Participants With (Serious) Adverse Event Related to the Medical Device — 0 Participants
N/A N=42 Tranexamic Acid for The Treatment of Gastrointestinal Bleeding
Gastrointestinal Bleeding
Primary: Re-bleeding — 6; 7 Participants
N/A N=341 Anticoagulation With Enhanced Gastrointestinal Safety
Upper Gastrointestinal Bleeding · Peptic Ulcer Hemorrhage · Anticoagulant-induced Bleeding
Primary: ITT Analysis - Percent of Patients Reporting Medication Optimization — 30; 2; 29; 65 Participants — p=<0.001
N/A N=131 PillSense System for Detecting UGI Bleed
UGI Bleed · Upper Gastrointestinal Bleeding · Upper Gastrointestinal Bleed
Primary: Sensitivity — 26 Participants
N/A N=66 Laparoscopic Peritoneal Lavage vs Laparoscopic Sigmoidectomy in Perforated Acute Diverticulitis: a Multicenter Prospective Observational Study (STELLA Study)
Acute Diverticulitis
Primary: Short-term Morbidity — 8; 1 Participants
N/A N=220 Management of Gastrointestinal and Urogenital (GI/GU) Bleedings in Atrial Fibrillation Patients Using Pradaxa
Atrial Fibrillation
Primary: Percentage of Patients With Index Event Safety Outcomes (Ongoing/Resolved/Deceased) at Time of Hospital Discharge — 19.1; 76.8; 4.1 Percentage of participants
N/A N=63 Anticoagulation With Enhanced Gastrointestinal Safety (AEGIS) Trial
Upper Gastrointestinal Bleeding
Primary: The Proportion of Randomized Patients That Complete a Brief Medication Review Phone Call at Week 5 — 7; 12; 8; 8 Participants
Phase 2 N=247 Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects
Gastroduodenal Ulceration
Primary: Incidence of Gastroduodenal Ulcers — 28; 34 participants
N/A N=20 Hemospray Versus the Combined Conventional Technique for Endoscopic Hemostasis of Bleeding Peptic Ulcers : A Pilot Study
Bleeding Peptic Ulcers
Primary: Re-bleeding Within 4 Weeks — 3; 1 Participants
Phase 2 N=55 Long-term Effects of Thalidomide for Recurrent Gastrointestinal Bleeding Due to Vascular Malformation
Obscure Gastrointestinal Bleeding · Angiodysplasia · Gastric Antral Vascular Ectasia
Primary: Participants Whose Rebleeds Decreased From Baseline by ≥ 50% at 12 Months — 20; 1 participants — p=0.00000013
Phase 1 N=10 Safety Study of Octreotide Injection to Prevent GI Bleeding in Patients With Left Ventricular Assist Device (LVAD)
Gastrointestinal Bleeding
Primary: Number of Participants With Side-Effects — 10 participants
Phase 4 N=90 Time Interval for Endoscopic Variceal Ligation
Variceal Bleeding
Primary: Proportion of Patients With Eradication of Esophageal Varices — 37; 23 Participants
Phase 4 N=88 Efficacy of Lactobacillus GG With Diosmectite in Treatment Children With Acute Gastroenteritis
Diarrhea
Primary: Duration of Diarrhea — 2; 2 days — p=0.43
Phase 4 N=60 Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy
Diabetes Mellitus, Type 2 · Obesity · Gastroparesis
Primary: Presence of RGV (Residual Gastric Volume) in Stomach — 7; 1 Participants
Phase 2 N=204 Endoscopic Evaluation of Upper Gastrointestinal (GI) Mucosal Damage Induced by PL-2200 Versus Aspirin in Healthy Volunteers
Upper Gastrointestinal Mucosal Damage
Primary: Incidence of Subjects With Gastroduodenal Erosions and Ulcers. — 72; 54; 19; 36 participants
Phase 2 N=18 Evaluation of Blood as a Submucosal Cushion During Endoscopic Polypectomy and Mucosal Resection
Large Polyps in the Gastrointestinal Tract
Primary: Duration of the Submucosal Cushion
N/A N=68 Comparison of Blood Product Use and Bleeding Events During and After Endoscopic or Neurosurgical Procedures in Patients With Cirrhosis and Coagulopathy
Cirrhosis · Coagulopathy
Primary: Intra-operative Blood Loss — 2000; 3000 milliliters
Phase 4 N=1,044 Polyethylene Glycol Versus Low Volume Solutions Prior to Colonoscopy
Colonoscopy
Primary: Quality of Bowel Preparation Using the Aronchick Scale ( Score 1+2) — 110; 145; 100; 134 Participants
Phase 3 N=394 BLI850 vs an Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy
Colon Cancer
Primary: Efficacy - Preparation Quality Using a 4 Point Scale — 90; 84 percentage of participants
Phase 3 N=971 Impact of Emergency Department Probiotic (LGG) Treatment of Pediatric Gastroenteritis
Gastroenteritis
Primary: Number of Participants With Modified Vesikari Scale Score >=9 — 55; 60 Participants — p=0.83
Phase 4 N=520 MoviPrep® Versus GoLYTELY® Bowel Preparation in Hospitalized Patients Undergoing Colonoscopy
Bowel Preparation Before Colonoscopy
Primary: Number of Participants With Adequate Bowel Preparation — 111; 111 Participants — p=0.007
N/A N=928 Safety of Endoscopic Resection of Large Colorectal Polyps: A Randomized Trial.
Colon Polyps
Primary: Number of Participants With Delayed Bleeding Complications — 16; 33 Participants